Agile therapeutics posts growth in third quarter results, reiterates confidence in target of $25m net revenue, positive cash flow in 2024

Princeton, nj / accesswire / november 22, 2023 / agile therapeutics, inc. (nasdaq:agrx), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for twirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal system, its birth control patch. the company also reiterated its target for full-year 2023 revenue of at least $25 million and to be cash flow positive from operations in the first quarter of 2024.
AGRX Ratings Summary
AGRX Quant Ranking